Compare MEOH & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEOH | ICUI |
|---|---|---|
| Founded | 1968 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 1995 | 1995 |
| Metric | MEOH | ICUI |
|---|---|---|
| Price | $54.38 | $166.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $58.33 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 998.9K | 271.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $25.43 | N/A |
| Revenue Next Year | N/A | $4.46 |
| P/E Ratio | ★ $16.44 | $138.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.00 | $107.02 |
| 52 Week High | $66.75 | $176.27 |
| Indicator | MEOH | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Methanex Corp operates as a producer and supplier of methanol to various international markets in North America, Asia Pacific, Europe and South America. The company's operations consist prominently of the production and sale of methanol, along with the production and sale of ammonia. Geographically, it operates in China, Europe, the United States, South America, South Korea, Other Asia, and Canada. The majority of revenue is derived from Europe.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.